2024
Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis
Gooderham M, Bunick C, Kircik L, Lynde C, Skov L, Blau J, Zhang W, Uy J, Winkelman W, Thaçi D. Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s442. DOI: 10.25251/skin.8.supp.442.Peer-Reviewed Original ResearchPhase 2b trialLaboratory parametersPlaque psoriasisCommon Terminology Criteria for Adverse Events grade 1Adverse Events grade 1Mild to moderate elevationMean triglyceride valuesPhase 3 studyAssessment of laboratory parametersAssociated with rhabdomyolysisTyrosine kinase 2 inhibitorCreatine kinaseJanus kinaseSerum cholesterol levelsDouble-blindPrimary endpointPsoriasis AreaCK elevationStudy treatmentLipid parametersTriglyceride valuesGrade 1PsoriasisCholesterol levelsPatientsNogo-B inhibition facilitates cholesterol metabolism to reduce hypercholesterolemia
Xue C, Zeng P, Gong K, Li Q, Feng Z, Wang M, Chen S, Yang Y, Li J, Zhang S, Yin Z, Liang Y, Yan T, Yu M, Feng K, Zhao D, Yang X, Zhang X, Ma L, Iwakiri Y, Chen L, Tang X, Chen Y, Chen H, Duan Y. Nogo-B inhibition facilitates cholesterol metabolism to reduce hypercholesterolemia. Cell Reports 2024, 43: 114691. PMID: 39235944, DOI: 10.1016/j.celrep.2024.114691.Peer-Reviewed Original ResearchLow-density lipoprotein receptorNogo-BCholesterol levelsCellular cholesterol levelsCholesterol excretionDecreased cellular cholesterol levelsATP-binding cassette transportersLiver x receptor-aHepatic uptakeLow-density lipoprotein receptor expressionCholesterol metabolic processHepatic cholesterol uptakeNogo-B expressionLowering cholesterol levelsMetabolic processesCassette transportersLipoprotein receptorApolipoprotein ELower cholesterol levelsCholesterol metabolismCholesterol uptakeDecreased cholesterol levelsReduce hypercholesterolemiaMolecular targetsExcretionRisk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification
Ghosh A, Venkatraman S, Nanna M, Safford M, Colantonio L, Brown T, Pinheiro L, Peterson E, Navar A, Sterling M, Soroka O, Nahid M, Banerjee S, Goyal P. Risk Prediction for Atherosclerotic Cardiovascular Disease With and Without Race Stratification. JAMA Cardiology 2024, 9: 55-62. PMID: 38055247, PMCID: PMC10701663, DOI: 10.1001/jamacardio.2023.4520.Peer-Reviewed Original ResearchConceptsLipoprotein cholesterol levelsAtherosclerotic cardiovascular diseaseCohort studyREGARDS cohortCholesterol levelsCardiovascular diseaseLow-density lipoprotein cholesterol levelsCoronary heart disease deathDensity lipoprotein cholesterol levelsRace-sex stratumHeart disease deathProspective cohort studyCohort risk equationsRisk predictionRace stratificationIncident ASCVDNonfatal strokeDisease deathsC-statisticMyocardial infarctionHigh riskRisk equationsSocial determinantsPercentage declineIncremental value
2023
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease. ESC Heart Failure 2023, 11: 737-747. PMID: 38155446, PMCID: PMC10966270, DOI: 10.1002/ehf2.14601.Peer-Reviewed Original ResearchPlacebo-treated participantsKidney eventsType 2 diabetesHeart failureCV eventsBaseline factorsLow-density lipoprotein cholesterol levelsMajor adverse CV eventsEMPA-REG OUTCOMEPrior heart failureAdverse CV eventsHeart failure eventsGlomerular filtration rateLipoprotein cholesterol levelsCoronary artery diseaseCox regression modelHigh uric acidUse of therapiesCardiovascular eventsCV diseaseHF outcomesArtery diseaseCholesterol levelsFiltration rateSubsequent riskAssociation between serum total cholesterol and chronic kidney disease progression in children: results from the KNOW-PedCKD
Baek H, Park M, Song J, Kim S, Kang H, Ahn Y, Han K, Cho H, Lee K, Shin J, Park Y, Lee J, Park E, Yang E, Cho M. Association between serum total cholesterol and chronic kidney disease progression in children: results from the KNOW-PedCKD. Pediatric Nephrology 2023, 38: 4101-4109. PMID: 37338642, DOI: 10.1007/s00467-023-06033-6.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseTotal cholesterol levelsChronic kidney disease progressionCox proportional hazards modelsSerum total cholesterolCKD progressionProportional hazards modelCholesterol levelsTotal cholesterolGraphical abstractA higher resolution versionLowered total cholesterol levelsProgression of chronic kidney diseaseHazards modelHigher serum total cholesterolPediatric chronic kidney diseaseKorean Cohort StudyKidney disease progressionTreatment of dyslipidemiaSerum total cholesterol levelsUnivariate analysisCohort studyDisease progressionHazard ratioMultivariate analysisKidney diseaseDeucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials
Lebwohl M, Strober B, Linaberry M, Hoyt K, Banerjee S, Kisa R, Mehta N. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal Of Cutaneous Medicine 2023, 7: s115. DOI: 10.25251/skin.7.supp.115.Peer-Reviewed Original ResearchSevere plaque psoriasisHDL cholesterolTotal cholesterolWeek 16Plaque psoriasisLDL cholesterolTriglyceride levelsLipid parametersWeeks 0Tyrosine kinase 2Treatment groupsDouble-blind trialBaseline triglyceride levelsLDL cholesterol levelsMean triglyceride levelsTreatment of adultsOral placeboMean triglyceridesAdverse eventsSerum lipidsSystemic therapyDL increasePsoriasis pathogenesisCholesterol levelsMean changeA Form of Metabolic-Associated Fatty Liver Disease Associated with a Novel LIPA Variant
Anushiravani A, Khamirani H, Mohamadkhani A, Mani A, Dianatpour M, Malekzadeh R. A Form of Metabolic-Associated Fatty Liver Disease Associated with a Novel LIPA Variant. Archives Of Iranian Medicine 2023, 26: 86-91. PMID: 37543928, PMCID: PMC10685898, DOI: 10.34172/aim.2023.14.Peer-Reviewed Original ResearchConceptsFatty liver diseaseVibration-controlled transient elastographyLiver diseaseLysosomal acid lipaseHomozygous missense variantCholesteryl ester storage diseaseWhole-exome sequencingMissense variantsLiver Disease AssociatedBody mass indexRoutine laboratory testsHigh cholesterol levelsSanger sequencingIranian familyFamily membersNovel missense variantLiPA resultsNASH cirrhosisSevere dyslipidemiaFatty liverMass indexDisease AssociatedCholesterol levelsTransient elastographyCirrhosis
2022
Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study
Cainzos‐Achirica M, Quispe R, Mszar R, Dudum R, Al Rifai M, Erbel R, Stang A, Jöckel K, Lehmann N, Schramm S, Schmidt B, Toth P, Rana J, Lima J, de Vasconcellos H, Lloyd‐Jones D, Joshi P, Ayers C, Khera A, Blaha M, Greenland P, Nasir K. Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study. Journal Of The American Heart Association 2022, 11: e025737. PMID: 35943062, PMCID: PMC9496288, DOI: 10.1161/jaha.122.025737.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterol levelsCoronary artery calciumAtherosclerotic cardiovascular diseaseLipoprotein cholesterol levelsClinically evident atherosclerotic cardiovascular diseaseSubclinical organ damageTraditional risk factorsHigh-risk scenariosRisk factorsAssociated with ASCVD eventsCholesterol levelsOrgan damageASCVD event ratesAtherosclerotic cardiovascular disease riskCoronary Artery Calcium TestingLow-density lipoprotein cholesterol <Coronary artery calcium scoreCoronary artery calcium burdenArtery calcium scoreASCVD eventsCalcium scoreArtery calciumFamilial hypercholesterolemiaPCSK9iMulticohort study
2021
MMAB promotes negative feedback control of cholesterol homeostasis
Goedeke L, Canfrán-Duque A, Rotllan N, Chaube B, Thompson BM, Lee RG, Cline GW, McDonald JG, Shulman GI, Lasunción MA, Suárez Y, Fernández-Hernando C. MMAB promotes negative feedback control of cholesterol homeostasis. Nature Communications 2021, 12: 6448. PMID: 34750386, PMCID: PMC8575900, DOI: 10.1038/s41467-021-26787-7.Peer-Reviewed Original ResearchMeSH KeywordsAlkyl and Aryl TransferasesAnimalsCell Line, TumorCholesterolCholesterol, LDLFeedback, PhysiologicalGene Expression ProfilingHeLa CellsHep G2 CellsHomeostasisHumansHydroxymethylglutaryl CoA ReductasesLiverMice, Inbred C57BLMice, KnockoutPromoter Regions, GeneticReceptors, LDLRNA InterferenceSterol Regulatory Element Binding Protein 2ConceptsCholesterol biosynthesisCholesterol homeostasisMouse hepatic cell lineIntegrative genomic strategyIntricate regulatory networkMaster transcriptional regulatorCellular cholesterol levelsHMGCR activityLDL-cholesterol uptakeCholesterol levelsHuman hepatic cellsSterol contentGenomic strategiesTranscriptional regulatorsRegulatory networksIntracellular cholesterol levelsGene expressionUnexpected roleHepatic cell linesBiosynthesisMMABIntracellular levelsCell linesHomeostasisExpression of SREBP2Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice
Singh AK, Chaube B, Zhang X, Sun J, Citrin KM, Canfrán-Duque A, Aryal B, Rotllan N, Varela L, Lee RG, Horvath TL, Price N, Suárez Y, Fernandez-Hernando C. Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice. Journal Of Clinical Investigation 2021, 131 PMID: 34255741, PMCID: PMC8409581, DOI: 10.1172/jci140989.Peer-Reviewed Original ResearchDiet-induced obesityGlucose intoleranceHigh-fat fed conditionsLipoprotein lipaseExcess hepatic lipid accumulationSystemic metabolic dysfunctionRole of ANGPTL4Liver lipid metabolismHepatic lipid accumulationTargeted pharmacologic therapyANGPTL4 gene expressionMetabolic turnover studiesHepatic lipase activityObesity-associated diabetesFatty acidsNovel inhibition strategiesPharmacologic therapyLiver steatosisLiver damageLipoprotein remnantsCholesterol levelsMetabolic dysfunctionHepatic uptakeANGPTL4 deficiencyHL activityGenetic determinants of LDL cholesterol and risk of intracerebral haemorrhage
Szejko N, Kirsch E, Falcone GJ. Genetic determinants of LDL cholesterol and risk of intracerebral haemorrhage. Current Opinion In Lipidology 2021, 32: 244-248. PMID: 34010223, PMCID: PMC10273781, DOI: 10.1097/mol.0000000000000761.Peer-Reviewed Original ResearchConceptsRisk of ICHIntracerebral hemorrhageLDL levelsLDL cholesterolInverse associationClinical trialsLipid levelsObservational studyCerebral small vessel diseaseWhite matter hyperintensity volumeLDL cholesterol levelsLow LDL levelsNontraumatic intracerebral hemorrhageSmall vessel diseaseElevated LDL levelsElevated lipid levelsVessel diseaseCholesterol levelsHigh burdenHyperintensity volumeHigh riskRole of lipidsHemorrhageStatinsRiskIs the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging
Xu M, Demuyakor A, Hu S, Liu H, Zhao C, Chen T, Qin Y, Xu Y, Feng X, Zeng M, Weng Z, Gao Z, Hou J, Jia H, Zhang S, Yu B. Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging. Catheterization And Cardiovascular Interventions 2021, 97: 1097-1107. PMID: 33864710, DOI: 10.1002/ccd.29654.Peer-Reviewed Original ResearchConceptsOptical coherence tomographyLipid-rich plaquesLipid lowering therapyEffect of atorvastatinFibrous cap thicknessStatin therapyLowering therapyCoherence tomographyIntensive lipid lowering therapySerial optical coherence tomographyCholesterol levelsLow-density lipoprotein cholesterol levelsIntravascular ultrasound imagingLipoprotein cholesterol levelsCholesterol level reductionLipid arcClinical benefitFollow-upPlaque volumeUltrasound imagingTherapyTherapy effectsPlaque burdenPercentage changeStatinsAllostatic Load Effects on Cortical and Cognitive Deficits in Essentially Normotensive, Normoweight Patients with Schizophrenia
Zhou Y, Huang J, Zhang P, Tong J, Fan F, Gou M, Cui Y, Luo X, Tan S, Wang Z, Feng W, Yang F, Tian B, Tian L, Savransky A, Hare S, Ryan MC, Goldwaser E, Chiappelli J, Chen S, Kochunov P, Kvarta M, Tan Y, Hong LE. Allostatic Load Effects on Cortical and Cognitive Deficits in Essentially Normotensive, Normoweight Patients with Schizophrenia. Schizophrenia Bulletin 2021, 47: 1048-1057. PMID: 33501486, PMCID: PMC8266595, DOI: 10.1093/schbul/sbaa196.Peer-Reviewed Original ResearchConceptsHigher allostatic loadCognitive deficitsCortical thicknessCortical thinningAllostatic loadCholesterol levelsSchizophrenia patientsLow high-density lipoprotein cholesterolHypersensitive C-reactive proteinHigh-density lipoprotein cholesterolLower total cholesterol levelsDiastolic blood pressureTotal cholesterol levelsC-reactive proteinWaist-hip ratioLeft superior frontal gyrusHigh cholesterol levelsMean cortical thicknessHigher heart rateSuperior frontal gyrusEarly intervention strategiesGray matter integrityNormoweight patientsLipoprotein cholesterolBlood pressure
2020
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Kho P, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Brinton L, Buchanan DD, Chanock SJ, Chen C, Chen MM, Cheng THT, Cook LS, Crous‐Bous M, Czene K, De Vivo I, Dennis J, Dörk T, Dowdy SC, Dunning AM, Dürst M, Easton DF, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, García‐Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankinson SE, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hunter DJ, Jones A, Kraft P, Krakstad C, Lambrechts D, Le Marchand L, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Milne RL, Mints M, Nassir R, Otton G, Palles C, Pooler L, Proietto T, Rebbeck TR, Renner SP, Risch HA, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu X, Southey MC, Tham E, Tomlinson I, Trovik J, Turman C, Tyrer JP, Van Den Berg D, Wang Z, Wentzensen N, Xia L, Xiang Y, Yang HP, Yu H, Zheng W, Webb PM, Thompson DJ, Spurdle AB, Glubb DM, O'Mara TA. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal Of Cancer 2020, 148: 307-319. PMID: 32851660, PMCID: PMC7757859, DOI: 10.1002/ijc.33206.Peer-Reviewed Original ResearchConceptsNon-endometrioid endometrial cancerEndometrial cancer riskEndometrial cancerLDL cholesterol levelsMendelian randomization analysisBlood lipidsCholesterol levelsCancer riskRandomization analysisLower endometrial cancer riskNon-endometrioid subtypesHDL cholesterol levelsBlood lipid levelsEndometrial cancer developmentRange of cancersTwo-sample Mendelian randomization (MR) analysisPotential confounding roleHDL cholesterolColorectal cancerLipid levelsObservational studyLower riskGlobal Lipids Genetics ConsortiumCancerInconsistent associationsGenetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage
Falcone GJ, Kirsch E, Acosta JN, Noche RB, Leasure A, Marini S, Chung J, Selim M, Meschia JF, Brown DL, Worrall BB, Tirschwell DL, Jagiella JM, Schmidt H, Jimenez‐Conde J, Fernandez‐Cadenas I, Lindgren A, Slowik A, Gill D, Holmes M, Phuah C, Petersen NH, Matouk CN, Gunel M, Sansing L, Bennett D, Chen Z, Sun LL, Clarke R, Walters RG, Gill TM, Biffi A, Kathiresan S, Langefeld CD, Woo D, Rosand J, Sheth KN, Anderson CD, Consortium F. Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage. Annals Of Neurology 2020, 88: 56-66. PMID: 32277781, PMCID: PMC7523882, DOI: 10.1002/ana.25740.Peer-Reviewed Original ResearchConceptsIntracerebral hemorrhagePolygenic risk scoresLDL cholesterolLower riskTotal cholesterolICH riskLow-density lipoprotein cholesterol levelsRisk of ICHLipoprotein cholesterol levelsPotential causal roleMendelian randomization analysisAnn NeurolLDL levelsCholesterol levelsICH casesObservational studySD increaseSignificant single nucleotide polymorphismsRisk scoreSignificant associationCholesterolMR analysisInverse correlationRandomization analysisSingle nucleotide polymorphisms
2019
Reduction in Serum Cholesterol in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P06-118-19)
Mehal W, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ouyang X, Ali A. Reduction in Serum Cholesterol in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P06-118-19). Current Developments In Nutrition 2019, 3: nzz031.p06-118-19. PMCID: PMC6576748, DOI: 10.1093/cdn/nzz031.p06-118-19.Peer-Reviewed Original ResearchTotal cholesterol levelsLDL cholesterolCholesterol levelsLipid parametersTotal cholesterolVisit 1Obese individualsPercentage changeTreatment total cholesterolSerum lipid profileMethods Prospective studyLDL cholesterol valuesPost treatmentVisit 7Clinic visitsHDL cholesterolObese subjectsLean subjectsProspective studyVisit 3Hypolipidemic effectsSerum cholesterolLean individualsLipid profileVisit 8
2018
Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program
Sun Y, Damrauer S, Hui Q, Assimes T, Ho Y, Natarajan P, Klarin D, Huang J, Lynch J, DuVall S, Pyarajan S, Honerlaw J, Gaziano J, Cho K, Rader D, O’Donnell C, Tsao P, Wilson P, Ramoni R, Breeling J, Chang K, Huang G, Muralidhar S, Muralidhar S, Moser J, Whitbourne S, Brewer J, Concato J, Warren S, Argyres D, Stephens B, Brophy M, Humphries D, Do N, Shayan S, Nguyen X, Hauser E, Sun Y, Zhao H, Wilson P, McArdle R, Dellitalia L, Harley J, Whittle J, Beckham J, Wells J, Gutierrez S, Gibson G, Kaminsky L, Villareal G, Kinlay S, Xu J, Hamner M, Haddock K, Bhushan S, Iruvanti P, Godschalk M, Ballas Z, Buford M, Mastorides S, Klein J, Ratcliffe N, Florez H, Swann A, Murdoch M, Sriram P, Yeh S, Washburn R, Jhala D, Aguayo S, Cohen D, Sharma S, Callaghan J, Oursler K, Whooley M, Ahuja S, Gutierrez A, Schifman R, Greco J, Rauchman M, Servatius R, Oehlert M, Wallbom A, Fernando R, Morgan T, Stapley T, Sherman S, Anderson G, Tsao P, Sonel E, Boyko E, Meyer L, Gupta S, Fayad J, Hung A, Lichy J, Hurley R, Robey B, Striker R. Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program. Circulation Genomic And Precision Medicine 2018, 11 PMID: 31106297, PMCID: PMC6516478, DOI: 10.1161/circgen.118.002192.Peer-Reviewed Original ResearchConceptsCoronary heart diseasePathogenic FH variantsFamilial hypercholesterolemiaFH variantsClinical outcomesHigh prevalenceLow-density lipoprotein cholesterolPremature coronary heart diseasePeripheral artery diseaseLDL-C levelsLow-density lipoproteinMulti-ethnic populationCardiovascular outcomesArtery diseaseLipoprotein cholesterolCholesterol levelsHeart diseaseMillion Veteran ProgramRisk individualsPhenome-wide scanGenetic Variants AssociatedClinical diagnosisClinical encountersHypercholesterolemiaMulti-ethnic participantsMild subclinical hypothyroidism is associated with paediatric dyslipidaemia
Dahl A, Iqbal A, Lteif A, Pittock S, Tebben P, Kumar S. Mild subclinical hypothyroidism is associated with paediatric dyslipidaemia. Clinical Endocrinology 2018, 89: 330-335. PMID: 29846957, DOI: 10.1111/cen.13752.Peer-Reviewed Original ResearchConceptsMild subclinical hypothyroidismElevated non-HDL cholesterolSubclinical hypothyroidismEuthyroid childrenElevated total cholesterolAssociated with higher ratesNon-HDL cholesterolTotal cholesterolLipid profilePresence of thyroid autoimmunityRandomized placebo-controlled studyNon-HDL cholesterol levelsAssociated with total cholesterolPlacebo-controlled studyMeasurement of TSHCompare lipid profilesTSH levelsThyroid autoimmunityHigher RatesFree thyroxineCardiometabolic consequencesOdds ratioControlled studiesCholesterol levelsHypothyroidism
2017
Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol
Chen Y, Xu C, Harirforoosh S, Luo X, Wang KS. Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol. Journal Of Psychiatric Research 2017, 96: 65-72. PMID: 28987514, PMCID: PMC6195678, DOI: 10.1016/j.jpsychires.2017.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedAged, 80 and overAlzheimer DiseaseCase-Control StudiesCerebellumCholesterolComputer SimulationFamilyGene ExpressionGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMiddle AgedNeoplasmsPolymorphism, Single NucleotideReceptor-Like Protein Tyrosine Phosphatases, Class 2ConceptsRisk of ADRisk of cancerAlzheimer's diseaseAAO of ADSingle nucleotide polymorphismsTotal cholesterol levelsMultiple logistic regressionLDL cholesterolTotal cholesterolCholesterol levelsAD patientsCancer riskMultiple linear regression analysisLinear regression analysisNeuropsychiatric disordersLogistic regressionDiseaseCancerWilcoxon testExpression levelsRiskRegression analysisGene expression levelsHuman brainGenetic variantsGeneric atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study
Loch A, Bewersdorf J, Kofink D, Ismail D, Abidin I, Veriah R. Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Research Notes 2017, 10: 291. PMID: 28716156, PMCID: PMC5514478, DOI: 10.1186/s13104-017-2617-6.Peer-Reviewed Original ResearchConceptsStatistically significant differenceEffective management of hyperlipidemiaHealth care costsSignificant differenceUniversity of Malaya Medical CentreRetrospective cohort studyHDL cholesterol levelsManagement of hyperlipidemiaLipid lowering effectsIncreased health care costsAtorvastatin formulationsLowering cholesterol levelsSwitching patientsCare costsLDL cholesterolMethodsThis cross-sectionalCohort studyLipid profileTotal cholesterolGeneric atorvastatinDrug efficacyAtorvastatinMedical CentreCholesterol levelsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply